iStock
May 14, 2021
Your heart valves are the small but mighty heroes of your circulatory system these four paper-thin membranes attached to the heart wall do a ton of work to keep your heart beating (and you, alive). In fact, they open and close a whopping 80 million times a year! So, keeping them strong and free of problems, like stenosis (when the valves thicken or stiffen) and regurgitation (when blood sneaks back through it the wrong direction) is crucial. How do you do that? With these smart lifestyle, diet, and health moves that will keep those little babies flapping with more ease.
May 16, 2021
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
“Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan,” Senthil Selvaraj, MD (Hospital of the University of Pennsylvania, Philadelphia), who presented the findings today at the American College of Cardiology 2021 Scientific Session, told TCTMD in an email. “Sacubitril/valsartan may be part of the therapeutic armamentarium is reducing triglycerides as adjunct therapy. However, outcomes studies looking at related cardiovascular endpoints in high-risk populations are needed.”
PARAGON-HF: Sacubitril/valsartan reduces triglyceride levels in HFpEF Source:
Selvaraj S, et al. Public Health and Heart Failure: Emerging Evidence. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting). Disclosures:
Selvaraj reports no relevant financial disclosures. Please see the study for the other authors’ relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
May 15, 2021
Emergent CABG surgery has seen waning use over the past few decades among patients hospitalized for acute MI in the United States, a trend not likely to come as a surprise to cardiologists watching PCI’s ascendance. But nationwide data also show that even as the patients targeted for CABG therapy have grown sicker and higher-risk, their in-hospital mortality rates have decreased.
The data, encompassing more than 11 million acute MI admissions from 2000 to 2017, were released today during the virtual American College of Cardiology (ACC) 2021 Scientific Session and simultaneously published online in the
Journal of the American Heart Association.
“There has been a near 90% reduction in the need for emergency CABG for acute myocardial infarction [over the years], primary due to the emergence of percutaneous coronary interventions and the associated outcomes,” Sri Harsha Patlolla, MBBS (Mayo Clinic, Rochester, MN), said when presenting the ACC abstract. Yet there
As the hype surrounding probiotics continues to soar so does our appetite for bug-laced fermented foods and drinks, including trendy kombucha. The probiotic-rich fermented tea has become way more visible in recent years as a bevy of brands have muscled their way onto beverage shelves with a rainbow of colors and enticing flavors.
Here’s the thing: I adore kombucha. The first time I sipped the vinegary drink after a hard-charging bike ride I was smitten. It contains the perfect blend of tang, sweetness, and effervescence. I also convinced myself that it’s gotta be
relatively healthy. After all, it has probiotics, right? Marketing words like “detox” and “renew” made it even easier to swallow the high price tag. It offered a much more interesting way to stay hydrated than yawning tap water.